Smith+Nephew, the global medical technology company, has announced findings from a newly published, first-of-its-kind comparative study of single-use negative pressure wound therapy (sNPWT) devices in orthopedic and cardiovascular surgery.
Analysing real-world data from over 22,000 patients in the Premier PINC AI Healthcare Database, the analysis reveals that prophylactic use of PICO sNPWT (-80 mmHg) significantly reduces surgical site complications (SSCs), hospital length of stay (LoS), and overall healthcare costs compared to the Prevena -125 mmHg sNPWT device.
An estimated 313 million surgical procedures are performed worldwide each year, with the number continuing to rise.
In the United States, surgical site infections (SSIs) occur in approximately 2 per cent to 4 per cent of patients undergoing inpatient procedures.
Study key findings include:
Cardiovascular Surgery (5,000+ patients)
- 8 per cent relative reduction in wound dehiscence risk (P<0.01)
- 1 per cent relative reduction in LoS (6.33 days vs. 6.86 days) (P<0.0001)
- 34 per cent relative reduction in admission-related costs and 13 per cent lower expenditures within three months post-surgery (P<0.0001)
Orthopedic Surgery (17,000+ patients)
- 9 per cent relative reduction in wound dehiscence incidence (p<0.05)
- 7 per cent relative reduction in LoS (2.43 days vs. 3.10 days) (p<0.0001)
- 95 per cent relative reduction in mean index admission cost and a 21 per cent reduction at 30- and 90-day post-surgery (p<0.001)
Substantial cost savings with PICO sNPWT
SSCs are associated with prolonged
